about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Dab­bling in CD47, Pfiz­er in­fus­es $25M in­to a biotech play­er tout­ing pos­i­tive monother­a­py da­ta

5 years ago
Deals
R&D

Covid-19 roundup: Cure­Vac ex­pands cache to $1.3B as coro­n­avirus race heats up; Russ­ian sci­en­tists pub­lish ear­ly da­ta ...

5 years ago
Coronavirus

Ab­b­Vie jumps in­to CD47 game, en­gi­neers $3B deal with am­bi­tious Chi­nese play­er

5 years ago
Deals
China

Mon­cef Slaoui calls late Oc­to­ber vac­cine roll­out 'ex­treme­ly un­like­ly,' vows again to re­sign un­der un­due po­lit­i­cal ...

5 years ago
Coronavirus

New tar­get­ed ther­a­py ap­proach­es win Rain Ther­a­peu­tics $63M — de­signed to beat a quick path to ap­proval

5 years ago
Financing
Startups

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M ini­tial ask

5 years ago
Financing
Cell/Gene Tx

En­thused by PhII au­toim­mune da­ta, J&J kept Mo­men­ta wait­ing in the lead-up to $6.5B buy­out

5 years ago
Deals

Weeks af­ter launch, Alex Zha­voronkov's AI-in­spired longevi­ty spin­out sells to Hong Kong-list­ed group

5 years ago
Deals
AI

Car­lyle Group in­jects $260M in­to a lead­ing car­dio play­er in Chi­na, grab­bing a seat at the deals ta­ble

5 years ago
Deals
China

Sanofi, Re­gen­eron hit fi­nal nail on the IL-6 re­pur­pos­ing cof­fin as Kevzara fails PhI­II

5 years ago
R&D
Coronavirus

No­var­tis says its Soliris add-on might be able to re­place the Alex­ion drug al­to­geth­er. But is it too late?

5 years ago
R&D

Un­fazed by slow roll­out, Nestlé buys out Aim­mune and its peanut al­ler­gy med for $2.6B

5 years ago
Deals

Covid-19 roundup: Most Amer­i­cans wor­ry pol­i­tics is put be­fore sci­ence amid vac­cine rush; Dai­ichi Sankyo fur­thers mR­NA ...

5 years ago
Coronavirus

Akcea shows off what No­var­tis missed and what Pfiz­er gained, of­fer­ing more de­tails on PhII car­dio da­ta

5 years ago
R&D

Glax­o­SmithK­line says it's one step clos­er to a func­tion­al hep B cure — but J&J and oth­er ri­vals are rush­ing there

5 years ago
R&D

Covid-19 roundup: J&J launch­ing new PhII vac­cine tri­als in Eu­rope; Ab­bott scores $760M test­ing kit or­der from HHS

5 years ago
Coronavirus

Covid-19 roundup: BeiGene snags rights to po­ten­tial an­ti­body treat­ment; Beef­ing up man­u­fac­tur­ing ops, Re­gen­eron adds ...

5 years ago
Coronavirus

Ex-Cel­gene ex­ec steers his biotech start­up to Hong Kong IPO as po­ten­tial can­cer drug launch looms

5 years ago
Financing
China

Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

5 years ago
News Briefing

Boehringer calls off €627M deal with GSK spin­out, pass­ing on schiz­o­phre­nia drug op­tion

5 years ago
Deals

Rid­ing on ear­ly can­cer de­tec­tion fren­zy, Freenome scores $270M to push liq­uid biop­sy tech be­yond col­orec­tal can­cer

5 years ago
Financing

Covid-19 roundup: Eu­ro­pean vac­cines lob­by push­ing for li­a­bil­i­ty pro­tec­tion; VBI vac­cines to prep hu­man tri­als

5 years ago
Coronavirus

Black­stone bankrolls sup­ply chain play­er's deal spree with $275M

5 years ago
Deals

Troy Wil­son re­cruits As­traZeneca vet to steer Ku­ra's late-stage piv­ot

5 years ago
People
First page Previous page 67686970717273 Next page Last page
A service from the Financial Times